Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe

COVID19 convalescent plasma (CCP) has proven an effective treatment for outpatients, and CCP collected from vaccinated donors is among the few effective therapeutic options for immunocompromised patients. Despite this, most countries are still relying over in-hospital compassionate usages outside cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Franchini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692823/
https://www.ncbi.nlm.nih.gov/pubmed/36362859
http://dx.doi.org/10.3390/life12111704
_version_ 1784837365716484096
author Focosi, Daniele
Franchini, Massimo
author_facet Focosi, Daniele
Franchini, Massimo
author_sort Focosi, Daniele
collection PubMed
description COVID19 convalescent plasma (CCP) has proven an effective treatment for outpatients, and CCP collected from vaccinated donors is among the few effective therapeutic options for immunocompromised patients. Despite this, most countries are still relying over in-hospital compassionate usages outside clinical trials. Given the need for early treatment, home transfusions are expecially needed. We review here the state of the art for out-of-hospital CCP transfusions and discuss solutions to potential burocratic hurdles.
format Online
Article
Text
id pubmed-9692823
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96928232022-11-26 Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe Focosi, Daniele Franchini, Massimo Life (Basel) Opinion COVID19 convalescent plasma (CCP) has proven an effective treatment for outpatients, and CCP collected from vaccinated donors is among the few effective therapeutic options for immunocompromised patients. Despite this, most countries are still relying over in-hospital compassionate usages outside clinical trials. Given the need for early treatment, home transfusions are expecially needed. We review here the state of the art for out-of-hospital CCP transfusions and discuss solutions to potential burocratic hurdles. MDPI 2022-10-26 /pmc/articles/PMC9692823/ /pubmed/36362859 http://dx.doi.org/10.3390/life12111704 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Focosi, Daniele
Franchini, Massimo
Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title_full Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title_fullStr Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title_full_unstemmed Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title_short Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
title_sort home and out-of-hospital therapy with covid-19 convalescent plasma in europe
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692823/
https://www.ncbi.nlm.nih.gov/pubmed/36362859
http://dx.doi.org/10.3390/life12111704
work_keys_str_mv AT focosidaniele homeandoutofhospitaltherapywithcovid19convalescentplasmaineurope
AT franchinimassimo homeandoutofhospitaltherapywithcovid19convalescentplasmaineurope

Ejemplares similares